The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its co-primary endpoints, demonstrating that BEYFORTUS provides protection for babies ...

A large-scale real-world study in the USA has reinforced the effectiveness of Beyfortus (nirsevimab-alip), the respiratory ...

A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

Beyfortus won FDA approval in July as a passive immunization for RSV-related lower respiratory tract disease in newborns and infants born during or entering their first RSV season, plus young kids ...

Beyfortus contains the active ingredient nirsevimab-alip,* and Synagis contains palivizumab. If you have other questions about how Beyfortus and Synagis compare, talk with your child’s doctor.

The second trial included 1490 term and late-preterm infants, of which 994 received Beyfortus; 1.2% of infants on Beyfortus were infected with MA RSV LRTI vs 5.0% in the placebo group.

Find out whether you should get the RSV vaccine, known as Abrysvo, during pregnancy and when it's recommended.

Beyfortus, provided directly to newborns and infants as a single dose, offers rapid protection via an antibody to help prevent LRTD caused by RSV, without requiring activation of the immune system ...

AstraZeneca’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks Consensus Estimate. Core earnings of $2.17 per share rose 10% year over ...

Sanofi has tripled Beyfortus production and doubled manufacturing sites since its 2023 launch. PPI and Industrial Production drop Wednesday morning — see how Matt Maley is trading the reaction ...